Effective postoperative pain management following tooth extraction has undergone a paradigm shift over the past decade. The opioid epidemic, landmark comparative effectiveness trials, and updated ADA and AAOMS guidance have collectively repositioned non-opioid multimodal analgesia as the standard of care for the vast majority of dental extraction procedures.
The current evidence base strongly supports a scheduled combination regimen of ibuprofen (400–600 mg q6–8h) plus acetaminophen (500–1000 mg q6h), administered around-the-clock for the first 48–72 hours, as superior to either agent alone and equivalent or superior to opioid-containing regimens for most extraction procedures.[1,2,3] Opioids, when warranted, should be reserved for documented inadequate response to maximized non-opioid therapy, prescribed at the lowest effective dose for the shortest duration (typically ≤3 days).[4,5]
Post-extraction pain is primarily inflammatory nociceptive pain arising from surgical trauma to the periodontal ligament, alveolar bone, and soft tissue. Prostaglandins (PGE₂, PGI₂), bradykinin, histamine, and substance P sensitize peripheral nociceptors within minutes of tissue injury. Peak pain intensity typically occurs 6–8 hours post-procedure for simple extractions and 12–24 hours for surgical third-molar removal.[6]
Central sensitization contributes to prolonged or heightened pain in a subset of patients, particularly those with pre-existing chronic pain or high pre-operative anxiety. This underpins the rationale for preemptive analgesia — blocking afferent nociceptive input before tissue injury to attenuate central sensitization.[7]
Dry socket (alveolar osteitis) — occurring in 1–4% of routine extractions and up to 38% of mandibular third-molar procedures — represents a distinct pain syndrome peaking at post-operative day 3–5, caused by premature clot lysis and exposure of alveolar bone. It requires separate management and is not simply an extension of normal post-extraction pain.[8]
A 2022 Cochrane systematic review of 40 RCTs (n=4,244) confirmed that preoperative NSAID administration significantly reduced peak VAS pain scores (WMD −12.4 mm) and analgesic consumption in the first 24 hours compared to placebo.[1] Ibuprofen 400–600 mg given 30–60 minutes pre-operatively is the most studied regimen. Ketorolac 30 mg IV/IM pre-operatively is supported for surgical cases requiring stronger anti-inflammatory effect.[9]
Dexamethasone at 4–8 mg (0.1 mg/kg pediatric) given IV/IM 30–60 minutes pre-operatively or intraoperatively significantly reduces post-operative swelling, trismus, and pain following surgical third-molar removal. A 2021 meta-analysis of 24 RCTs found dexamethasone reduced maximum pain VAS by 18.3 mm (95% CI 13.1–23.5) compared to placebo, with no significant increase in infection or dry socket risk at single-dose administration.[10]
IV acetaminophen 1000 mg administered 15–30 minutes pre-operatively has been shown to reduce postoperative opioid consumption and pain scores in outpatient surgical settings.[12] Oral acetaminophen 1000 mg given 1 hour pre-operatively is a practical and cost-effective alternative where IV access is unavailable.[13]
Inferior alveolar nerve block (IANB) and buccal/lingual infiltrations with long-acting local anesthetics are the cornerstone of intraoperative and early postoperative analgesia. Bupivacaine 0.5% with epinephrine 1:200,000 provides 4–8 hours of post-operative pain control and is the preferred agent for surgical cases.[14] Compared to lidocaine, bupivacaine significantly reduces early postoperative analgesic consumption.[15]
Liposomal bupivacaine (266 mg/20 mL) delivers extended-release bupivacaine over 72–96 hours. A 2023 multicenter RCT (n=446) demonstrated significantly lower pain scores at 24, 48, and 72 hours post third-molar extraction with a 41% reduction in opioid rescue medication use.[16] The 2024 AAOMS guideline conditionally recommends liposomal bupivacaine for complex surgical extractions, noting cost as a limitation for routine use.[5]
Ketorolac 15–30 mg IV administered intraoperatively (after hemostasis) provides powerful perioperative anti-inflammatory analgesia. A 2020 RCT demonstrated that single-dose intraoperative ketorolac 30 mg IV reduced postoperative VAS pain by 23% at 6 hours.[9] Use is limited to ≤5 days total per FDA labeling.
Acetaminophen 1000 mg has NNT = 3.6 for post-dental pain (Cochrane), lower than NSAIDs but with a superior safety profile and no platelet or renal effects. Essential as a combination partner due to complementary mechanisms.[18]
Multiple meta-analyses demonstrate that ibuprofen 400 mg + acetaminophen 1000 mg produces superior analgesia (NNT ≈ 1.5–1.8) compared to opioid combinations including hydrocodone/acetaminophen, codeine/acetaminophen, and tramadol, with significantly fewer adverse effects.[2,3,19]
The 2023 ADA policy and 2024 AAOMS guidelines state that opioids should not be first-line analgesics for routine dental extractions.[4,5] When used:
While primarily used preoperatively, a second dose of dexamethasone at 8 hours post-extraction has been shown in a 2023 RCT to extend anti-inflammatory benefit without suppressing wound healing.[11] Routine multiday steroid courses are not recommended due to risk of impaired healing, adrenal suppression, and infection.
Application of ice packs to the extraoral face (20 min on/20 min off) during the first 24–48 hours reduces postoperative swelling and pain via vasoconstriction and decreased inflammatory mediator release. A 2021 systematic review of 11 RCTs found cryotherapy significantly reduced edema (SMD −0.87) and pain (SMD −0.74) at 24–48 hours.[21]
Autologous PRF placed into extraction sockets releases growth factors (PDGF, TGF-β, VEGF) that accelerate socket healing. A 2022 meta-analysis (18 RCTs, n=1,203) found PRF significantly reduced dry socket incidence (RR 0.31, 95% CI 0.18–0.53) and postoperative pain at 3–5 days.[22]
LLLT at 660–980 nm applied immediately post-extraction modulates mitochondrial activity and reduces inflammatory cytokines. A 2023 meta-analysis (15 RCTs) demonstrated significant reduction in postoperative pain VAS at 24h (WMD −1.42, 95% CI −1.98 to −0.86) with no adverse events.[23]
Alveolar osteitis (dry socket) is the most common post-extraction complication. Risk factors include mandibular location, impacted third molars, tobacco use, oral contraceptive use, traumatic extraction, and inadequate irrigation. Standard pain medications provide minimal relief; treatment requires local management.
Prior to 2015, prescribing 5–20 tablets of hydrocodone/acetaminophen as routine post-extraction analgesia was common. Key practice-changing milestones include:
Population-level data show dental opioid prescriptions decreased by approximately 32% between 2012 and 2022, with no population-level increase in ED visits for uncontrolled dental pain.[25]
| Drug | Standard Adult Dose | Pediatric Dose | Timing | Route | Frequency | Max Daily Dose | Evidence Level |
|---|---|---|---|---|---|---|---|
| PREOPERATIVE | |||||||
| Ibuprofen | 400–600 mg | 5–10 mg/kg | 30–60 min pre-op | PO | One-time pre-op dose | 600 mg single | IA — Cochrane SR 2022 |
| Acetaminophen | 1000 mg | 15 mg/kg | 60 min pre-op | PO or IV | One-time pre-op dose | 1000 mg single | IB — Multiple RCTs |
| Dexamethasone | 4–8 mg | 0.08–0.1 mg/kg | 30–60 min pre-op | IV/IM | Single dose (±2nd dose 8h post) | 8 mg | IA — Meta-analysis 2021 |
| Ketorolac | 30 mg | 0.5 mg/kg (max 30 mg) | 30 min pre-op or intraop | IV/IM | Single dose | 30 mg | IB — RCT 2020 |
| INTRAOPERATIVE | |||||||
| Bupivacaine 0.5% + epi 1:200,000 | 1.8–5.4 mL | Max 2 mg/kg | At nerve block | Infiltration/Block | Single administration | 2 mg/kg | IA — Standard of care |
| Liposomal bupivacaine (Exparel) | 266 mg (20 mL) | Not approved <6 yrs | After hemostasis confirmed | Local infiltration | Single administration | 266 mg | IB — RCT 2023 |
| Lidocaine 2% + epi 1:100,000 | 1.8–3.6 mL | 4.4 mg/kg max | At nerve block | Infiltration/Block | Single administration | 7 mg/kg with epi | IA — Standard of care |
| POSTOPERATIVE — SCHEDULED (1st Line) | |||||||
| Ibuprofen | 400–600 mg | 5–10 mg/kg (max 400 mg) | Start at procedure end | PO | Q6–8h × 48–72h | 2400 mg (OTC); 3200 mg (Rx) | IA — ADA 2023, Cochrane |
| Acetaminophen | 500–1000 mg | 10–15 mg/kg | Interleaved with ibuprofen | PO | Q6h × 48–72h | 3000–4000 mg | IA — ADA 2023 |
| Ibuprofen 400 mg + Acetaminophen 1000 mg | Combination | As above per weight | Interleaved q3h effectively | PO | Q6h each, alternating q3h | As above per agent | IA — JAMA 2018, confirmed 2021/2023 |
| Naproxen sodium | 550 mg then 275 mg | 5–7.5 mg/kg | Post-procedure | PO | Q8–12h | 1100 mg | IB — Cochrane |
| Celecoxib | 200–400 mg | Not approved <2 yrs | Post-procedure | PO | Q12h × 48–72h | 400 mg | IB — High GI-risk patients |
| POSTOPERATIVE — RESCUE (2nd Line) | |||||||
| Hydrocodone/APAP 5/325 mg | 5/325 mg | Not recommended <18 | Breakthrough only | PO | Q4–6h PRN × ≤3 days | 30 mg hydrocodone | IIB — Limited to refractory |
| Oxycodone IR | 5 mg | Not recommended <18 | Breakthrough only | PO | Q4–6h PRN × ≤3 days | 30 mg oxycodone | IIB — Limited to refractory |
| Tramadol | 50–100 mg | Not recommended <18 | Breakthrough only | PO | Q6h PRN × ≤3 days | 400 mg | IIC — NNT 8.2, avoid |
Evidence Levels: IA = meta-analysis of RCTs; IB = single large RCT; IIB = smaller RCTs or high-quality cohort; IIC = consensus/expert opinion. APAP = acetaminophen.
| Drug/Combination | NNT (≥50% relief) | Onset (min) | Duration (h) | Common Adverse Effects | Key Contraindications |
|---|---|---|---|---|---|
| Ibuprofen 400 mg | 2.5 | 30–45 | 4–6 | GI upset, dyspepsia | Active PUD, severe renal impairment, CABG periop, 3rd trimester pregnancy |
| Ibuprofen 600 mg | 2.4 | 30–45 | 6–8 | GI upset (↑ vs 400 mg), hypertension | Same as above; ↑ CV risk with prolonged use |
| Ibuprofen 400 mg + Acetaminophen 1000 mg | 1.5–1.8 | 30–45 | 6–8 | Low combined rate | Avoid in severe hepatic (APAP component) |
| Acetaminophen 1000 mg | 3.6 | 45–60 | 4–6 | Hepatotoxicity (overdose) | Severe hepatic impairment; alcohol use disorder |
| Naproxen sodium 550 mg | 2.9 | 30–60 | 8–12 | GI, fluid retention | Renal impairment, heart failure, 3rd trimester |
| Diclofenac K 50 mg | 2.7 | 15–30 | 4–6 | GI, transaminase elevation | Hepatic impairment, PUD |
| Celecoxib 200 mg | 3.5 | 30–60 | 8–12 | ↓ GI vs non-selective NSAIDs; minimal ↑ CV risk at short courses | Sulfonamide allergy, severe CV disease |
| Celecoxib 400 mg | 3.2 | 30–60 | 12 | Same as 200 mg (↑) | Same; use lowest effective dose |
| Ketorolac 30 mg IV | 1.8 | 5–15 | 4–6 | GI bleeding, renal injury | Renal impairment, active bleeding, ≤5 days only |
| Hydrocodone/APAP 5/325 | 3.5–4.0 | 30–45 | 4–6 | Nausea, constipation, sedation, dependence | Respiratory depression risk, substance use disorder, concurrent CNS depressants |
| Oxycodone 5 mg | 2.3–3.0 | 30–45 | 4–6 | Nausea, constipation, sedation, dependence | Same as hydrocodone; ↑ abuse potential |
| Tramadol 100 mg | 8.2 | 30–60 | 4–6 | Nausea, dizziness, serotonin syndrome risk | MAO inhibitor use, seizure disorder, CYP2D6 polymorphism |
| Codeine 60 mg | 12.3 | 30–60 | 4–6 | Nausea, constipation, unpredictable analgesia | Children <18 (post-surgical), CYP2D6 ultra-rapid metabolizers |
| Dexamethasone 8 mg | N/A (anti-inflammatory) | 30–60 (IV) | 24–48 | Hyperglycemia, insomnia (single dose low risk) | Active infection (relative), DM (monitor glucose) |
| Bupivacaine 0.5% block | N/A (local) | 5–10 | 4–8 | Cardiac toxicity (overdose) | Allergy to amide local anesthetics |
| Liposomal bupivacaine | N/A (local) | 15–30 | 60–72 | Local irritation; cardiotoxicity if overdosed | Do not mix with other local anesthetics |
NNT = Number Needed to Treat for ≥50% pain relief vs. placebo. Sources: Cochrane Acute Pain Group meta-analyses; Moore 2018 JAMA; Derry 2022 Cochrane.
| Guideline / Source | Year | Key Recommendation | Opioid Stance | Evidence Grade |
|---|---|---|---|---|
| ADA Clinical Policy: Opioid Prescribing | 2023 | NSAIDs ± acetaminophen are drugs of choice for acute dental pain. Opioids should be avoided when non-opioid therapy is effective. | Avoid first-line; prescribe ≤3 days if needed; minimum quantity | Strong recommendation |
| AAOMS Evidence-Based CPG: Third Molar Removal | 2024 | Multimodal analgesia (NSAID + APAP ± dexamethasone ± long-acting local anesthetic) strongly recommended. Liposomal bupivacaine: conditional recommendation for complex cases. | Routine prescribing not recommended; reserved for refractory pain | Strong (multimodal); Conditional (liposomal bupivacaine) |
| CDC Clinical Practice Guideline — Opioid Prescribing | 2022 | For acute pain: use lowest effective non-opioid dose; if opioids needed, ≤3 days typically sufficient; ≤7 days rarely needed. | Non-opioid preferred; limit quantity; co-prescribe naloxone in high-risk | Clinical recommendation (evidence-based) |
| Cochrane Review: NSAIDs for Dental Pain (Derry et al.) | 2022 | Single-dose ibuprofen 400–600 mg is the most effective and best-studied analgesic for acute dental pain. Combinations with APAP provide superior relief. | Opioid combinations inferior to ibuprofen + APAP | High-quality evidence (Grade A) |
| Cochrane Review: Paracetamol for Dental Pain (Toms et al., updated) | 2023 | Paracetamol 1000 mg provides effective analgesia (NNT 3.6) and is valuable as combination therapy with NSAIDs. | N/A | Moderate-quality evidence (Grade B) |
| Cochrane Review: Corticosteroids for Third Molar Pain | 2021 | Single-dose dexamethasone 4–8 mg significantly reduces post-operative pain, swelling, and trismus; does not increase dry socket or infection at single-dose. | N/A | Moderate-quality evidence (Grade B) |
| FDA Drug Safety Communication: Codeine in Children | 2017 | Codeine and tramadol are contraindicated in children <12; codeine contraindicated in adolescents <18 for post-surgical pain. | Absolute contraindication in children | Regulatory (Black Box Warning) |
| UK NICE Guideline NG191: Acute Pain | 2021 | For moderate-to-severe acute pain: ibuprofen preferred over opioids; paracetamol as adjunct; minimize opioid use. | Opioids only after non-opioid failure | NICE Grade B |
| Tier | Procedure Type | Preoperative | Intraoperative | Postoperative (Scheduled) | Rescue (PRN) | Duration | Notes |
|---|---|---|---|---|---|---|---|
| TIER 1 | Simple extraction (single tooth, erupted, minimal bone removal) | None required OR ibuprofen 400 mg PO 1h pre-op | Lidocaine 2% + epi 1:100,000 IANB/infiltration | Ibuprofen 400 mg PO q6–8h × 24–48h ± APAP 500 mg q6h | APAP 1000 mg PO PRN if ibuprofen inadequate | 24–48 hours | Vast majority of adult extractions. No opioids warranted. |
| TIER 2 | Multiple simple extractions OR single partially erupted tooth | Ibuprofen 600 mg PO 30–60 min pre-op | Bupivacaine 0.5% + epi 1:200,000 nerve block | Ibuprofen 600 mg PO q6h + APAP 1000 mg PO q6h (interleaved q3h) | Hydrocodone/APAP 5/325 × 4–6 tabs PRN breakthrough only | 48–72 hours scheduled | Counsel patients: opioids are backup; most will not need them. |
| TIER 3 | Surgical extraction of single impacted third molar (soft tissue/partial bony) | Dexamethasone 4–8 mg IV/IM + ibuprofen 600 mg PO | Bupivacaine 0.5% + epi; consider PRF socket placement | Ibuprofen 600 mg q6h + APAP 1000 mg q6h × 72h | Oxycodone 5 mg or hydrocodone/APAP 5/325 × 8–10 tabs PRN; limit 3 days | 72 hours scheduled; reassess at 72h | Standard current approach for most OMSs. Dexamethasone significantly reduces trismus and swelling. |
| TIER 4 | Surgical removal of multiple fully impacted third molars (complete bony) | Dexamethasone 8 mg IV/IM + ibuprofen 600 mg PO + APAP 1000 mg PO | Bupivacaine 0.5% IANB bilateral + liposomal bupivacaine (if available) + PRF socket placement | Ibuprofen 600 mg q6h + APAP 1000 mg q6h × 72–96h | Oxycodone 5 mg PRN × ≤3 days; consider scheduled opioid only if NRS ≥7 on optimized non-opioid | 72–96 hours scheduled; opioid ≤3 days | Liposomal bupivacaine may obviate need for opioids in many patients. |
| TIER 5 | Dry socket / Alveolar osteitis (complication) | N/A | Local management: saline irrigation + obtundent dressing | Ibuprofen 600 mg q6h + APAP 1000 mg q6h; maximize before escalating | Oxycodone 5–10 mg q4–6h PRN × 3–5 days; reassess daily | Until local dressing controls pain (typically 3–7 days) | Local dressing is primary therapy; systemic analgesics adjunctive. Opioid more justifiable here; still limit quantity. |
| Population | Recommended Drugs | Dose Modification | Drugs to Avoid | Rationale / Notes |
|---|---|---|---|---|
| Pediatric (2–12 yrs) | Ibuprofen 5–10 mg/kg/dose (max 400 mg) APAP 10–15 mg/kg/dose | Weight-based; max ibuprofen 40 mg/kg/day; APAP 75 mg/kg/day | Codeine (absolute CI), tramadol, opioids generally, aspirin | FDA Black Box Warning: Codeine/tramadol contraindicated <12 yrs (post-surgical <18). Aspirin: Reye syndrome risk. |
| Adolescent (12–18 yrs) | Ibuprofen 400 mg q6–8h APAP 500–1000 mg q6h | Standard adult doses if >40 kg | Codeine, tramadol (both contraindicated <18 for post-surgical) | FDA 2017 labeling change. If opioid truly required (rare): low-dose oxycodone with parental supervision; ≤3 days. |
| Pregnancy (1st/2nd trimester) | APAP 500–1000 mg q6h (preferred) Short-course ibuprofen acceptable in 1st trimester only | Standard doses; avoid prolonged course | NSAIDs in 3rd trimester (all); opioids if avoidable; dexamethasone (relative CI) | APAP safest throughout. NSAIDs: premature ductus arteriosus closure risk after 20 weeks; absolute CI after 30 wks (FDA 2020 warning). |
| Pregnancy (3rd trimester, >30 wks) | APAP 500–1000 mg q6h ONLY | Standard doses | ALL NSAIDs (absolute CI), opioids if avoidable | FDA 2020: NSAIDs after 20 wks may cause fetal renal dysfunction and oligohydramnios; absolute CI after 30 wks. |
| Lactating Women | Ibuprofen 400–600 mg q6–8h (preferred NSAID) APAP 500–1000 mg q6h | Standard doses | Codeine (ultra-rapid metabolizer risk to infant), high-dose aspirin | Ibuprofen: minimal transfer to breast milk (M/P ratio 0.008–0.015). Codeine: absolute CI — neonatal deaths reported. |
| Renal Impairment (eGFR 30–59) | APAP 500–1000 mg q8h Celecoxib 200 mg (cautiously) Short-course ibuprofen (1–2 doses only) | APAP: reduce frequency if eGFR 30–59 (q8h); avoid if eGFR <30 | All NSAIDs with eGFR <30; ketorolac at any level of renal impairment | NSAIDs: prostaglandin-dependent renal perfusion; risk of AKI. Ketorolac: highest nephrotoxic risk. |
| Renal Impairment (eGFR <30 / Dialysis) | APAP 500 mg q8h Oxycodone 2.5–5 mg q6–8h PRN (with dose reduction) | Significant dose interval extension; monitor carefully | ALL NSAIDs (absolute CI), ketorolac, tramadol, codeine | Tramadol: O-desmethyltramadol accumulates → seizure/serotonin syndrome risk. Opioids: active metabolites accumulate. |
| Hepatic Impairment (Child-Pugh A/B) | Ibuprofen 400 mg q8h (short course) APAP: reduce to 500 mg q8h max 2g/day Celecoxib with caution | APAP max 2g/day in any hepatic impairment | High-dose APAP, full-dose ibuprofen long-term, ketorolac | Reduced APAP glucuronidation; risk of DILI. NSAIDs: ↑ GI bleeding risk with portal hypertension. |
| Hepatic Impairment (Child-Pugh C / Severe) | Low-dose opioid under specialist guidance only APAP maximum 1g/day (if at all) | Extreme caution; specialist co-management | NSAIDs (all), full-dose APAP, ketorolac, tramadol | Coagulopathy common in severe liver disease: NSAIDs ↑ bleeding; APAP hepatotoxic threshold very low. |
| Elderly (≥65 years) | Ibuprofen 200–400 mg q8h (short course, with food) APAP 500 mg q6h (preferred for mild-moderate) Celecoxib 100–200 mg if GI risk | Reduce NSAID doses and duration; APAP max 3000 mg/day; consider PPI co-prescription | High-dose NSAIDs, tramadol (↑ falls, seizure), codeine | AGS Beers Criteria (2023): NSAIDs — lowest dose, shortest duration, add PPI, monitor renal function. Tramadol: Beers listed as avoid or use with caution. |
| Anticoagulants (Warfarin) | APAP 500–1000 mg q6h (1st line) Celecoxib 200 mg if NSAID required | Monitor INR if APAP used >1g/day × >3 days | All non-selective NSAIDs, ibuprofen, ketorolac | NSAIDs: platelet inhibition + GI mucosal damage → GI bleed risk markedly ↑ on warfarin. APAP: minimal platelet effect; preferred. |
| Anticoagulants (DOACs) | APAP 500–1000 mg q6h Short-course ibuprofen 400 mg q8h (1–2 days) with GI protection if necessary | Minimize NSAID duration | Ketorolac, high-dose or prolonged NSAIDs | DOACs + NSAIDs: ↑ GI bleeding risk. Drug interactions between rivaroxaban/apixaban and celecoxib (shared CYP3A4): use with awareness. |
| Opioid Use Disorder | Maximize APAP + Ibuprofen combination Dexamethasone preoperatively Liposomal bupivacaine (if available) | Standard doses; maximize non-opioid coverage aggressively | Opioids (high diversion/misuse risk); tramadol | If opioid truly necessary: co-prescribe with addiction medicine provider; do NOT stop buprenorphine/naloxone (MOUD); prescribe minimum quantity. |
AGS = American Geriatrics Society. CI = Contraindicated. DILI = Drug-Induced Liver Injury. DOAC = Direct Oral Anticoagulant. MOUD = Medications for Opioid Use Disorder. eGFR = estimated Glomerular Filtration Rate (mL/min/1.73m²).